ADMA Stock Analysis: ADMA Biologics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.146m USD | 12M Return: -45.7% | US0008991046 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 21.4M
Qual. Beats: 0
Rev. Trend: 94.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics, primarily targeting immune deficiencies and infectious diseases. It operates through two segments: ADMA BioManufacturing (production) and Plasma Collection Centers (sourcing of source plasma), reflecting a vertically integrated model that controls the supply chain from plasma collection through finished product manufacturing.
The companys marketed products include BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies for primary humoral immunodeficiency (PI), and Nabi-HB, a polyclonal antibody for Hepatitis B post-exposure prophylaxis. ADMA also maintains a development pipeline focused on immunoglobulin-based treatments for S. pneumonia infection, and runs its own source plasma collection facilities to support manufacturing inputs.
Products are sold through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers, both in the United States and internationally. ADMA Biologics was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
- IVIG product revenue accelerates on ASCENIV demand
- Plasma center expansion improves vertical integration margins
- Path to sustained profitability drives operating leverage
| Net Income: 169.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 5.24 > 1.0 |
| NWC/Revenue: 88.32% < 20% (prev 68.46%; Δ 19.86% < -1%) |
| CFO/TA 0.20 > 3% & CFO 136.7m > Net Income 169.0m |
| Net Debt (75.4m) to EBITDA (224.6m): 0.34 < 3 |
| Current Ratio: 6.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (230.3m) vs 12m ago -7.35% < -2% |
| Gross Margin: 64.71% > 18% (prev 53.00%; Δ 11.70% > 0.5%) |
| Asset Turnover: 82.45% > 50% (prev 84.92%; Δ -2.47% > 0%) |
| Interest Coverage Ratio: 24.53 > 6 (EBIT TTM 216.5m / Interest Expense TTM 8.82m) |
| A: 0.66 (Total Current Assets 528.2m - Total Current Liabilities 75.8m) / Total Assets 684.2m |
| B: -0.11 (Retained Earnings -78.5m / Total Assets 684.2m) |
| C: 0.35 (EBIT TTM 216.5m / Avg Total Assets 621.3m) |
| D: 1.48 (Book Value of Equity 408.2m / Total Liabilities 276.0m) |
| Altman-Z'' = 7.86 = AAA |
| DSRI: 1.17 (Receivables 138.2m/109.7m, Revenue 512.3m/474.2m) |
| GMI: 0.82 (GM 53.00% / 64.71%) |
| AQI: 0.74 (AQ_t 0.12 / AQ_t-1 0.17) |
| SGI: 1.08 (Revenue 512.3m / 474.2m) |
| TATA: 0.05 (NI 169.0m - CFO 136.7m) / TA 684.2m) |
| Beneish M = -3.15 (Cap -4..+1) = AA |
As of August 07, 2026, the stock is trading at USD 10.06 with a total of 5,556,616 shares traded. Over the past week, the price has changed by +16.03%, over one month by +9.83%, over three months by -0.20% and over the past year by -45.74%.
Current recommended Stop Loss: 9.60 (which is 4.6% or 1.4 ATR below the current price).
ADMA Biologics has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ADMA.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17 | 69% |
P/E Trailing = 13.0423
P/E Forward = 10.1937
P/S = 4.2094
P/B = 5.0235
Revenue TTM = 512.3m USD
EBIT TTM = 216.5m USD
EBITDA TTM = 224.6m USD
Long Term Debt = 69.3m USD (from longTermDebt, last fiscal year)
Short Term Debt = 4.93m USD (from shortTermDebt, last quarter)
Debt = 211.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.54m
Net Debt = 75.4m USD (calculated: Debt 211.4m - CCE 136.0m)
Enterprise Value = 2.22b USD (2.15b + Debt 211.4m - CCE 136.0m)
Interest Coverage Ratio = 24.53 (Ebit TTM 216.5m / Interest Expense TTM 8.82m)
EV/FCF = 19.07x (Enterprise Value 2.22b / FCF TTM 116.5m)
FCF Yield = 5.24% (FCF TTM 116.5m / Enterprise Value 2.22b)
FCF Margin = 22.74% (FCF TTM 116.5m / Revenue TTM 512.3m)
Net Margin = 32.98% (Net Income TTM 169.0m / Revenue TTM 512.3m)
Gross Margin = 64.71% ((Revenue TTM 512.3m - Cost of Revenue TTM 180.8m) / Revenue TTM)
Gross Margin QoQ = 69.36% (prev 70.53%)
Tobins Q-Ratio = 3.25 (Enterprise Value 2.22b / Total Assets 684.2m)
Interest Expense / Debt = 4.17% (Interest Expense 8.82m / Debt 211.4m)
Taxrate = 21.95% (47.5m / 216.5m)
NOPAT = 169.0m (EBIT 216.5m * (1 - 21.95%))
Current Ratio = 6.97 (Total Current Assets 528.2m / Total Current Liabilities 75.8m)
Debt / Equity = 0.52 (Debt 211.4m / totalStockholderEquity, last quarter 408.2m)
Debt / EBITDA = 0.34 (Net Debt 75.4m / EBITDA 224.6m)
Debt / FCF = 0.65 (Net Debt 75.4m / FCF TTM 116.5m)
Total Stockholder Equity = 426.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 27.19% (Net Income 169.0m / Total Assets 684.2m)
RoE = 39.59% (Net Income TTM 169.0m / Total Stockholder Equity 426.8m)
RoCE = 43.64% (EBIT 216.5m / Capital Employed (Equity 426.8m + L.T.Debt 69.3m))
RoIC = 28.75% (NOPAT 169.0m / Invested Capital 587.8m)
WACC = 6.79% (E(2.15b)/V(2.36b) * Re(7.14%) + D(211.4m)/V(2.36b) * Rd(4.17%) * (1-Tc(0.22)))
Discount Rate = 7.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -25.72 | Cagr: -1.15%
[DCF] Terminal Value 77.97% ; FCFF base≈96.2m ; Y1≈110.3m ; Y5≈162.3m
[DCF] Fair Price = 10.21 (EV 2.44b - Net Debt 75.4m = Equity 2.37b / Shares 231.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.76 | Revenue CAGR: 35.13% | SUE: -0.09 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.20 | Chg30d=-4.84% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=0.80 | Chg30d=-2.04% | Revisions=-25% | GrowthEPS=+21.3% | GrowthRev=+4.7%
EPS next Year (2027-12-31): EPS=0.98 | Chg30d=-1.25% | Revisions=-25% | GrowthEPS=+23.6% | GrowthRev=+31.1%
[Analyst] Revisions Ratio: -50% (up=0, down=3)